{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T19:15:11Z","timestamp":1769109311844,"version":"3.49.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,1,5]]},"DOI":"10.7759\/cureus.12511","type":"journal-article","created":{"date-parts":[[2021,1,6]],"date-time":"2021-01-06T01:18:28Z","timestamp":1609895908000},"source":"Crossref","is-referenced-by-count":2,"title":["Use of Botulinum Toxin A to Treat Chemotherapy-Induced Raynaud\u2019s Phenomenon"],"prefix":"10.7759","author":[{"given":"Thrisha K","family":"Potluri","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank G","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ethan","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sean J","family":"Wallace","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathan","family":"Miller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clindermatol.2018.04.007","article-title":"Raynaud's phenomenon: current concepts","volume":"36","author":"Stringer T","year":"2018","unstructured":"Stringer T, Femia AN. Raynaud's phenomenon: current concepts. Clin Dermatol. 2018, 36:498-507. 10.1016\/j.clindermatol.2018.04.007","journal-title":"Clin Dermatol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)05118-7","article-title":"Raynaud's phenomenon","volume":"357","author":"Block JA","year":"2001","unstructured":"Block JA, Sequeira W. Raynaud's phenomenon. Lancet. 2001, 357:2042-2048. 10.1016\/S0140-6736(00)05118-7","journal-title":"Lancet"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2019.101474","article-title":"Raynaud's phenomenon","volume":"34","author":"Herrick AL","year":"2020","unstructured":"Herrick AL, Wigley FM. Raynaud's phenomenon. Best Pract Res Clin Rheumatol. 2020, 34:101474. 10.1016\/j.berh.2019.101474","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12912","article-title":"Drug-induced Raynaud's phenomenon: beyond \u03b2-adrenoceptor blockers","volume":"82","author":"Khouri C","year":"2016","unstructured":"Khouri C, Blaise S, Carpentier P, Villier C, Cracowski JL, Roustit M. Drug-induced Raynaud's phenomenon: beyond \u03b2-adrenoceptor blockers. Br J Clin Pharmacol. 2016, 82:6-16. 10.1111\/bcp.12912","journal-title":"Br J Clin Pharmacol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-95-3-288","article-title":"Raynaud's phenomenon: a common toxicity after combination chemotherapy for testicular cancer","volume":"95","author":"Vogelzang NJ","year":"1981","unstructured":"Vogelzang NJ, Bosl GJ, Johnson K, Kennedy BJ. Raynaud's phenomenon: a common toxicity after combination chemotherapy for testicular cancer. Ann Intern Med. 1981, 95:288-292. 10.7326\/0003-4819-95-3-288","journal-title":"Ann Intern Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.2000.03448.x","article-title":"Digital necrosis related to cisplatin in systemic sclerosis","volume":"142","author":"Marie I","year":"2000","unstructured":"Marie I, Levesque H, Plissonnier D, Balguerie X, Cailleux N, Courtois H. Digital necrosis related to cisplatin in systemic sclerosis. Br J Dermatol. 2000, 142:833-834. 10.1046\/j.1365-2133.2000.03448.x","journal-title":"Br J Dermatol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-019-04762-4","article-title":"Optimisation of botulinum toxin type a treatment for the management of Raynaud's phenomenon using a dorsal approach: a prospective case series","volume":"38","author":"Dhaliwal K","year":"2019","unstructured":"Dhaliwal K, Griffin MF, Salinas S, Howell K, Denton CP, Butler PEM. Optimisation of botulinum toxin type a treatment for the management of Raynaud's phenomenon using a dorsal approach: a prospective case series. Clin Rheumatol. 2019, 38:3669-3676. 10.1007\/s10067-019-04762-4","journal-title":"Clin Rheumatol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhsa.2008.11.026","article-title":"Botulinum toxin type A: a treatment option for digital ischemia in patients with Raynaud's phenomenon","volume":"34","author":"Fregene A","year":"2009","unstructured":"Fregene A, Ditmars D, Siddiqui A. Botulinum toxin type A: a treatment option for digital ischemia in patients with Raynaud's phenomenon. J Hand Surg Am. 2009, 34:446-452. 10.1016\/j.jhsa.2008.11.026","journal-title":"J Hand Surg Am"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2362.2004.01324.x","article-title":"Botulinum toxin in the treatment of Raynaud's phenomenon: a pilot study","volume":"34","author":"Sycha T","year":"2004","unstructured":"Sycha T, Graninger M, Auff E, Schnider P. Botulinum toxin in the treatment of Raynaud's phenomenon: a pilot study. Eur J Clin Invest. 2004, 34:312-313. 10.1111\/j.1365-2362.2004.01324.x","journal-title":"Eur J Clin Invest"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.hcl.2014.09.003","article-title":"The role of botulinum toxin in vasospastic disorders of the hand","volume":"2015","author":"Neumeister MW","unstructured":"Neumeister MW. The role of botulinum toxin in vasospastic disorders of the hand. Hand Clin. 2015:23-37. 10.1016\/j.hcl.2014.09.003","journal-title":"Hand Clin"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1111\/j.1533-2500.2007.00122.x","article-title":"Treatment of refractory ischemic pain from chemotherapy-induced Raynaud's syndrome with spinal cord stimulation","volume":"7","author":"Ting JC","year":"2007","unstructured":"Ting JC, Fukshansky M, Burton AW. Treatment of refractory ischemic pain from chemotherapy-induced Raynaud's syndrome with spinal cord stimulation. Pain Pract. 2007, 7:143-146. 10.1111\/j.1533-2500.2007.00122.x","journal-title":"Pain Pract"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.annonc.a057750","article-title":"Vascular toxicity and the mechanism underlying Raynaud's phenomenon in patients treated with cisplatin, vinblastine and bleomycin","volume":"1","author":"Hansen SW","year":"1990","unstructured":"Hansen SW, Olsen N, Rossing N, R\u00f8rth M. Vascular toxicity and the mechanism underlying Raynaud's phenomenon in patients treated with cisplatin, vinblastine and bleomycin. Ann Oncol. 1990, 1:289-292. 10.1093\/oxfordjournals.annonc.a057750","journal-title":"Ann Oncol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.43.2872","article-title":"Bleomycin-induced Raynaud's phenomenon after single-dose exposure: risk factors and treatment with intravenous iloprost infusion","volume":"31","author":"McGrath SE","year":"2013","unstructured":"McGrath SE, Webb A, Walker-Bone K. Bleomycin-induced Raynaud's phenomenon after single-dose exposure: risk factors and treatment with intravenous iloprost infusion. J Clin Oncol. 2013, 31:51-52. 10.1200\/JCO.2012.43.2872","journal-title":"J Clin Oncol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-2665","article-title":"Efficacy of botulinum toxin B Injection for Raynaud's phenomenon and digital ulcers in patients with systemic sclerosis","volume":"97","author":"Motegi SI","year":"2017","unstructured":"Motegi SI, Uehara A, Yamada K, et al.. Efficacy of botulinum toxin B Injection for Raynaud's phenomenon and digital ulcers in patients with systemic sclerosis. Acta Derm Venereol. 2017, 97:843-850. 10.2340\/00015555-2665","journal-title":"Acta Derm Venereol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1097\/01.prs.0000244860.00674.57","article-title":"Management of vasospastic disorders with botulinum toxin A","volume":"119","author":"Van Beek AL","year":"2007","unstructured":"Van Beek AL, Lim PK, Gear AJ, Pritzker MR. Management of vasospastic disorders with botulinum toxin A. Plast Reconstr Surg. 2007, 119:217-226. 10.1097\/01.prs.0000244860.00674.57","journal-title":"Plast Reconstr Surg"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2013.06.029","article-title":"A pilot study evaluating the efficacy of botulinum toxin A in the treatment of Raynaud phenomenon","volume":"69","author":"Jenkins SN","year":"2013","unstructured":"Jenkins SN, Neyman KM, Veledar E, Chen SC. A pilot study evaluating the efficacy of botulinum toxin A in the treatment of Raynaud phenomenon. J Am Acad Dermatol. 2013, 69:834-835. 10.1016\/j.jaad.2013.06.029","journal-title":"J Am Acad Dermatol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2011.07.006","article-title":"Botulinum toxin A treatment of Raynaud's phenomenon: a review","volume":"41","author":"Iorio ML","year":"2012","unstructured":"Iorio ML, Masden DL, Higgins JP. Botulinum toxin A treatment of Raynaud's phenomenon: a review. Semin Arthritis Rheum. 2012, 41:599-603. 10.1016\/j.semarthrit.2011.07.006","journal-title":"Semin Arthritis Rheum"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.5114\/aoms.2015.48152","article-title":"Botulinum toxin A in the treatment of Raynaud\u2019s phenomenon: a systematic review","volume":"12","author":"\u017bebryk P","year":"2016","unstructured":"\u017bebryk P, Puszczewicz MJ. Botulinum toxin A in the treatment of Raynaud\u2019s phenomenon: a systematic review. Arch Med Sci. 2016, 12:864-870. 10.5114\/aoms.2015.48152","journal-title":"Arch Med Sci"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000005092","article-title":"A case report of the beneficial effects of botulinum toxin type A on Raynaud phenomenon in a patient with lung cancer","volume":"95","author":"Wang L","year":"2016","unstructured":"Wang L, Lei Q-S, Liu Y-Y, Song G-J, Song C-L. A case report of the beneficial effects of botulinum toxin type A on Raynaud phenomenon in a patient with lung cancer. Medicine (Baltimore). 2016, 95:5092. 10.1097\/MD.0000000000005092","journal-title":"Medicine (Baltimore)"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhsa.2020.07.009","article-title":"Botulinum toxin for the treatment of intractable Raynaud phenomenon","volume":"46","author":"Gallegos JE","year":"2020","unstructured":"Gallegos JE, Inglesby DC, Young ZT, Herrera FA. Botulinum toxin for the treatment of intractable Raynaud phenomenon. J Hand Surg Am. 2020, 46:54-59. 10.1016\/j.jhsa.2020.07.009","journal-title":"J Hand Surg Am"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/47434-use-of-botulinum-toxin-a-to-treat-chemotherapy-induced-raynauds-phenomenon","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:32:21Z","timestamp":1707507141000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/47434-use-of-botulinum-toxin-a-to-treat-chemotherapy-induced-raynauds-phenomenon"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,5]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.12511","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1,5]]}}}